John S. Bradley, MD is involved in Phase I through Phase IV clinical trials of antibacterials, antifungals, and non-HIV antivirals, and currently focuses on novel therapies for CA-MRSA. He has been involved in clinical trial design and evaluation of clinical trial data, as a member of the FDA’s Anti-Infective Drug Advisory Committee, incorporating pharmacodynamics and Monte Carlo Simulation into clinical outcome assessment. He is a member of the Foundation of NIH Biomarkers Consortium to create clinical trial design to better evaluate impact of anti-infective therapy.
Dr. Bradley's publications on PubMed
Grant Campbell, PhD studies the mechanisms that control autophagy in response to HIV-1 and M. tuberculosis infection by developing our understanding of how the endo/lysosomal system of macrophages is converted into providing a niche environment for controlled replication by M. tuberculosis and HIV-1. With a view to controlling infection, he is in the process of identifying pharmacological agents that induce autophagic flux and inhibit both HIV-1 and M. tuberculosis in macrophages. Through this work he has shown that the active metabolite of vitamin D induces autophagy and inhibits both HIV-1 and M. tuberculosis infection of macrophages.
John Leake, MD, MPH, has a primary clinical and research interest in tropical medicine, and has experience in field and laboratory investigation. He is currently collaborating with the UC San Diego (UCSD) Department of Medicine and Scripps Translational Science Institute on a leptospirosis immunogenetic susceptibility project. Other recent work includes a collaboration with UCSD and The Scripps Research Institute on study of the genetic basis of Plasmodium vivax chloroquine resistance in Indonesia. He also represents RCHSD through Baylor University/Texas Children’s Hospital in a multi-center U.S. collaborative project on meningococcal disease surveillance with eight other pediatric centers.
Dr. Leake's publications on PubMed
Alice Pong, MD has a keen interest in pediatric tuberculosis and participates in collaborative studies defining the cellular immune responses of children with acute and latent tuberculosis infections. Current research includes studying the efficacy of an interferon gamma assay to detect tuberculosis infection in children. She is also involved in clinical research studies related to infection control and currently is studying the impact of mupirocin on MRSA colonization in hospitalized children.
Dr. Pong's publications on PubMed
Mark H. Sawyer, MD focuses his research activities on immunizations through a contract with the San Diego County Health and Human Services Agency Immunization Program. This program is involved in all aspects of immunization including immunization policy, assessment of immunization coverage levels, education of providers and the community about immunizations, promotion of San Diego’s computerized regional immunization information system, and focused research into ways to improve immunization delivery.
Kumud K. Singh, PhD lab is involved in understanding the unique role of innate immunity in HIV-1 neuropathogenesis and neurodegenerative diseases. His lab focuses on how complement activation in HIV-1 infected brain leads to immune complex deposition, neuroinflammatory cytokine response and HIV-1 associated neurocognitive disorders. The Singh lab hypothesizes that complement activation is a common mechanism of neuroinflammation and CNS impairment due to an infection (HIV), autoimmunity (multiple sclerosis) and aging related consequences (Alzheimer’s disease).
Dr. Kumud Singh - Innate/Adaptive Immunity Interface Research Lab
Dr. Singh's publications on PubMed
Stephen A. Spector, MD has sought to discover novel approaches for the detection, treatment, prevention and immunopathogenesis of HIV and human cytomegalovirus (CMV). His laboratory has been involved with HIV/AIDS research since the beginning of the epidemic. Current ongoing research examines HIV pathogenesis with a particular emphasis on host-virus interactions, and the associations of host genetic variants on HIV diseases progression and HIV-related diseases including CNS impairment in children and adults. The laboratory’s interest in the identification of host factors that affect HIV pathogenesis led to the novel finding that during permissive infection, HIV down-regulates autophagy to promote its own replication, and the induction of autophagy (using mTOR inhibitors as well as vitamin D3) inhibits HIV replication. The laboratory has also identified specific host genetic variants that are associated with mother-to-child transmission, HIV disease progression, and antiretroviral pharmacokinetics and adverse effects. This research has led to his laboratory examining the association of host factors that control HIV replication with the goal of identifying novel strategies to eradicate HIV from those infected. Dr. Spector also directs the Mother-Child-Adolescent HIV Program that provides care, social service, case management and research opportunities for HIV-infected and affected women, pregnant women, youth and children.
Dr. Stephen Spector Lab
Dr. Spector's publications on PubMed
Rolando M. Viani, MD, MTP,
studies bi-national health for pregnant women and children infected with HIV. As part of the UCSD-Tijuana General Hospital Bi-National Program, Dr. Viani has established a model of care that is being replicated throughout Mexico. Dr. Viani and colleagues have determined that over 1.2% of pregnant women tested for HIV during delivery were HIV-infected, more than 10 times the number estimated by Mexican health officials. In addition to demonstrating the higher-than-expected HIV seroprevalence among pregnant women, Dr. Viani also demonstrated that women were willing to be tested for HIV and were interested in learning how to prevent their babies from becoming infected. Dr. Viani’s studies at Tijuana General Hospital also identified the risk factors for HIV infection among women and established the current baseline antiretroviral resistance rate among this population. Dr. Viani is also a leader in research involving primary viral resistance in HIV-infected adolescents. In addition, Dr. Viani has been involved as study chair and co-chair in the development of a Phase I/II NIH sponsored studies on the use of novel antiretrovirals with diverse mechanisms of action such as vicriviroc, a novel CCR5 antagonist, etravirine, a non-nucleoside analogue and dolutegravir, an integrase inhibitor in HIV infected treatment experienced children and adolescents. Recently, Dr. Viani has been studying the cellular immune response to tuberculosis in HIV infec ted children at both sides of the border.
Dr. Viani's publications on PubMed